Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

COPENHAGEN, Denmark— 12 March 2018

Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has commenced the clinical study for its lead compound AP30663. Acesion is developing a portfolio of drugs addressing both paroxysmal (acute) and persistent AF.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...